Otsuka launches pivotal trial of digital therapeutics for depression
Otsuka Pharmaceutical is partnering with Click Therapeutics to launch a remote clinical trial to evaluate the effectiveness of digital therapeutics in reducing depressive symptoms.
To avoid crisis, pharma must address costs
Scrutiny of drug prices will continue whether Trump or Biden wins. But pharma can take steps to address critics and cut costs before they reach a crisis point, according to a panel of industry experts.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Court approves Otsuka’s bid to buy Proteus for $15M
A bankruptcy court in Delaware approved a stalking-horse bid from Otsuka to acquire Proteus Digital Health for $15 million. The company, which makes sensor that can be embedded in pills to track medication adherence, filed for bankruptcy in June.
Proteus files for bankruptcy: Where did it falter?
After its partnership with Otsuka Pharmaceutical began to unravel earlier this year, Proteus Digital Health filed for bankruptcy on Monday. The company had raised more than $500 million to develop ‘smart pills’ embedded with sensors, but struggled to sell physicians and insurers on the technology.
Alphabet’s Verily boosts its Project Baseline with new health system, pharma partners
The company just announced strategic alliances with Novartis, Otsuka, Pfizer and Sanofi to develop new clinical research programs utilizing the Project Baseline platform across therapeutic areas ranging from cardiovascular disease to oncology to mental health.
More than half of patients willing to use digital therapeutic, study says
The report also found that 56 percent of physicians have brought up the potential for a digital therapy as an option for their patients, and 26 percent have discussed the option after a patient brought it up.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Digital medicine startup Proteus Digital Health pushes into oncology
Proteus' new oral oncology drug is a digital version of capecitabine, a common chemotherapy medication often used to treat breast and gastrointestinal cancers.
Here’s Otsuka’s digital health strategy around mental health
Otsuka's top U.S.-based leaders spoke about the company's partnerships in mental health and how it is driving innovation in big pharma.
Roche’s Venclexta data from ASH position drug as new AML standard of care, doctor says
The drug, combined with Celgene's Vidaza, Otsuka's Dacogen or low-dose cytarabine, showed strong response rates in elderly and unfit AML patients, historically a hard-to-treat population.
‘Under-the-radar’ companies could become hot acquisition targets in 2018
Nearly a dozen companies were identified in a report as potentially attractive for buyouts by larger firms. Japanese companies could be big players.
Maximize Revenue and Patient Care with Strategic Weight Loss Management
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Digital medicine Take 2: Proteus Digital Health, Otsuka resubmit FDA application
After more than one year since the FDA sent Proteus Digital Health and Otsuka back to the drawing board with a complete response letter on their joint initiative for a digital medicine to track the body's response to a drug, they've resubmitted the NDA